Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Purpose: Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared characteristics of patients enrolled in Lung-MAP with those of patients in advanced non-small-cell lung cancer (NSCLC) trials to examine if master protocols improve trial access.

Methods: We examined patients enrolled in Lung-MAP (2014-2020) according to sociodemographic characteristics. Proportions for characteristics were compared with those for a set of advanced NSCLC trials (2001-2020) and the US advanced NSCLC population using SEER registry data (2014-2018). Characteristics of patients enrolled in Lung-MAP treatment substudies were examined in subgroup analysis. Two-sided tests of proportions at an alpha of .01 were used for all comparisons.

Results: A total of 3,556 patients enrolled in Lung-MAP were compared with 2,215 patients enrolled in other NSCLC studies. Patients enrolled in Lung-MAP were more likely to be 65 years and older (57.2% 46.3%; < .0001), from rural areas (17.3% 14.4%; = .004), and from socioeconomically deprived neighborhoods (42.2% 36.7%, < .0001), but less likely to be female (38.6% 47.2%; < .0001), Asian (2.8% 5.1%; < .0001), or Hispanic (2.4% 3.8%; = .003). Among patients younger than 65 years, Lung-MAP enrolled more patients using Medicaid/no insurance (27.6% 17.8%; < .0001). Compared with the US advanced NSCLC population, Lung-MAP under represented patients 65 years and older (57.2% 69.8%; < .0001), females (38.6% 46.0%; < .0001), and racial or ethnic minorities (14.8% 21.5%; < .0001).

Conclusion: Master protocols may improve access to trials using novel therapeutics for older patients and socioeconomically vulnerable patients compared with conventional trials, but specific patient exclusion criteria influenced demographic composition. Further research examining participation barriers for under represented racial or ethnic minorities in precision medicine clinical trials is warranted.